Table 1

Effect of rituximab on circulating CD20/CD19-positive B cellsa

PatientDay 1bDay 7bDay 10Day 43c
14.5<0.10<0.1
214.9<0.1nddnd
320.50.10.04nd
429.8nd0.1e1.5
529.5<0.01<0.1<0.1
  • a CD20/CD19-positive B cells as percentage of circulating lymphocytes. Rituximab (375 mg/m2) was administered on days 1 and 7.

  • b ±2 days.

  • c ±8 days.

  • d nd, not done.

  • e Day 16.